Q4 2024 Earnings Call Transcript March 27, 2025 Relmada Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.62, expectations were $-0.7. Operator: Greetings, and welcome to the Relmada ...

The FDA approved neoadjuvant Imfinzi, gemcitabine and cisplatin, followed by adjuvant Imfinzi after radical cystectomy in ...

The FDA has approved neoadjuvant durvalumab plus chemotherapy followed by adjuvant durvalumab after radical cystectomy in MIBC.

This approval of durvalumab marks the first and only perioperative immunotherapy regimen available in muscle-invasive bladder ...

Jocelyn and Kristofer Carella-Erickson detail their traumatic back-to-back cancer experiences with PEOPLE — and say their ...

Exercise could potentially reduce the recurrence rate of breast cancer, new research from Edith Cowan University (ECU) has ...

Leveraging the power of AI and machine learning technologies, researchers at Weill Cornell Medicine developed a more ...

Pfizer's $25 support holds strong, with institutional buying signals and growth potential in oncology. Click here to read an ...